Previous 10 | Next 10 |
Xencor (NASDAQ: XNCR ) Q3 results ($M): Revenues: 29.0 (from Novartis collaboration and $9M in milestone payments from Alexion). More news on: Xencor, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Xencor, Inc. (NASDAQ:XNCR) Q3 2018 Earnings Conference Call November 5, 2018 4:30 PM ET Executives Charles Liles - Associate Director and Head of Corporate Communications and Investor Relations Bassil Dahiyat - Co-Founder, CEO, President & Director Paul Foster – SVP,...
Xencor (NASDAQ: XNCR ): Q3 GAAP EPS of $0.05 beats by $0.57 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
MONROVIA, Calif. , Nov. 5, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for t...
Thinly trade Xencor ( XNCR +11.7% ) is up on below-average volume following its announcement initial data from a Phase 1 dose-escalation study evaluating XmAb 14045 in patients with relapsed/refractory acute myeloid leukemia (AML). The results will be presented at ASH next month. More ...
MONROVIA, Calif. , Nov. 1, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced that initial data from its ongoin...
MONROVIA, Calif. , Oct. 29, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will re...
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CSG Systems International, Inc. (NASDAQ:CSGS), Zumiez Inc. (NASDAQ:ZUM...
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...
HSGX -43% on pricing public offering of common stock and warrants. More news on: Histogenics Corporation, KemPharm, Aytu BioScience, Inc., Stocks on the move, Top stock market news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through ...
2024-06-04 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...